Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Financial Results

Every financial results filing by a US-listed company that our alert engine sent, newest first.

6:05 AM ET 10-Q
Financial Results TCW Direct Lending VII LLC

TCW Direct Lending VII Q3 2026 Results: Net Loss of $22.5M

TCW Direct Lending VII LLC reported total investments of $1.16 billion at fair value as of September 30, 2026, with a significant concentration in debt investments across industries like Textiles, Apparel & Luxury Goods and Hotels, Restaurants & Leisure. The company's net assets stood at $400.2 million, supported by 13,734,010 common units outstanding.

Key figure
Net loss $22.5M
6:05 AM ET 10-Q
Financial Results TCW Direct Lending Viii LLC

TCW Direct Lending Viii Q3 2026 Results: Net Income $4.42M, Down 90.9% YoY

TCW Direct Lending VIII LLC reported a diverse portfolio of debt investments across industries such as automobile components, commercial services, and food products as of September 30, 2026. The company held 6,310,260 common units outstanding and maintained significant positions in term loans with varying SOFR-based interest rates and PIK components.

Key figure
Net income $4.42M · -90.9% YoY
6:05 AM ET 10-Q
Financial Results TCW Direct Lending LLC

TCW Direct Lending Q3 2026 Results: Net Loss of $5.99M, Loss Narrows

For the nine months ended September 30, 2026, TCW Direct Lending Strategic Ventures LLC reported a net decrease in members' capital from operations of $8.4 million, compared to a $4.2 million decrease in the prior year period. The decline was primarily driven by $9.7 million in net unrealized depreciation on affiliated investments, specifically related to SSI Parent, LLC common and preferred stock.

Key figure
Net loss $5.99M
6:05 AM ET 10-Q
Financial Results Reviva Pharmaceuticals Holdings, Inc. RVPH

Reviva Pharmaceuticals Holdings Q3 2026 Results: Net Loss of $2.3M, Loss Narrows

Reviva Pharmaceuticals reported a net loss of $7.9 million for the nine months ended September 30, 2026, a significant reduction from the $16.5 million loss in the prior year period. The company strengthened its liquidity through public and ATM offerings, ending the quarter with $17.5 million in cash and cash equivalents.

Key figure
Net loss $2.3M
6:05 AM ET 10-Q
Financial Results Bio Essence Corp BIOE

Bio Essence Q3 2026 Results: Net Loss of $150K

Bio Essence Corp. reported a net income of $324,992 for the nine months ended September 30, 2026, a significant improvement from a net loss of $132,890 in the prior year period. Despite this profitability, the company maintains a working capital deficit of $1,374,178 and an accumulated deficit of over $9.2 million, leading management to express substantial doubt about its ability to continue as a going concern.

Key figure
Net loss $150K
6:05 AM ET 8-K
Financial Results Reviva Pharmaceuticals Holdings, Inc. RVPH

Reviva Pharmaceuticals Holdings Financial Results

Reviva Pharmaceuticals reported a net loss of $2.3 million for the third quarter of 2026, an improvement from a $4.0 million loss in the prior year period. The company is awaiting FDA feedback in Q4 2026 regarding a new formulation of brilaroxazine for its Phase 3 RECOVER-2 trial in schizophrenia. Reviva also noted it has filed a new composition of matter patent application that could extend protection for brilaroxazine through 2046.

Term
Q3 2026

“Our near-term focus is obtaining Food and Drug Administration (FDA) feedback on the proposed use of a new formulation of brilaroxazine and preparing for the next stages of clinical development while managing our capital resources carefully.”

Laxminarayan Bhat, Founder, President, and CEO of Reviva

“We remain focused on disciplined execution as we advance brilaroxazine as a potentially differentiated treatment option for patients with schizophrenia.”

Laxminarayan Bhat, Founder, President, and CEO of Reviva
6:04 AM ET 10-Q
Financial Results Aardvark Therapeutics, Inc. AARD

Aardvark Therapeutics Q3 2026 Results: Net Loss of $19.2M, Loss Widens

Aardvark Therapeutics reported a net loss of $19.2 million for the third quarter of 2026, driven by increased research and development costs. The company's cash position remains at $60.3 million as it continues to transition from its 2025 initial public offering to fund its clinical-stage metabolic disease pipeline.

Key figure
Net loss $19.2M
6:04 AM ET 6-K
Financial Results Almonty Industries Inc. ALM

Almonty Industries Q3 2026 Results: Net Income $50.2M, Up 51.4% YoY

Almonty Industries reported a 382% year-over-year revenue increase to $41.9 million for Q3 2026, driven by a surge in tungsten prices and the commencement of commercial operations at the Sangdong Mine. Net income reached $50.2 million, supported by significant non-cash gains on derivative revaluations, while the company ended the quarter with a strong cash position of $1.15 billion.

Key figure
Net income $50.2M · +51.4% YoY
6:04 AM ET 10-Q
Financial Results Buda Juice, Inc. BUDA

Buda Juice Q3 2026 Results: Net Income $866K, Down 1.7% YoY

Buda Juice, Inc. reported net sales of $13.22 million for the nine months ended September 30, 2026, a significant increase from $9.71 million in the prior year. Following its January 2026 IPO and conversion to a C corporation, the company ended the period with $19.28 million in cash and cash equivalents, up from $1.84 million at the start of the year.

Key figure
Net income $866K · -1.7% YoY
6:04 AM ET 10-Q
Financial Results Realloys Inc. ALOY

Realloys Q3 2026 Results: Net Loss of $30.5M, Loss Widens

REALLOYS INC. reported a significant increase in net revenues to $1.92 million for the nine months ended September 30, 2026, compared to $0.63 million in the prior year, though it incurred a substantial net loss of $174.1 million driven by high general and administrative expenses and stock-based compensation. The company completed a reverse recapitalization in February 2026 and significantly strengthened its cash position to $116.2 million following various equity issuances.

Key figure
Net loss $30.5M
6:04 AM ET 8-K
Financial Results Skyx Platforms Corp. SKYX

Skyx Platforms Financial Results

SKYX Platforms reported record third-quarter revenue of $25.7 million, representing 7.4% year-over-year growth and its 11th consecutive quarter of growth. The company highlighted its recent merger with Deako, which expanded its builder channel pipeline to approximately 4 million units. Management noted a strong cash position of $21 million and believes it has sufficient capital to reach cash-flow positive status.

Term
Q3 2026
6:04 AM ET 8-K
Financial Results Nakamoto Inc. NAKA

Nakamoto Financial Results

Nakamoto Inc. reported Q3 2026 net income of $85.5 million, driven primarily by a $110.4 million gain in the fair value of its digital asset holdings. The company reported total operating revenue of $(1.9) million due to derivative losses and highlighted the extension of its Kraken loan facility maturity to December 2027.

Term
Q3 2026

“We spent the third quarter building. We launched Bitcoin Magazine TV to add year-round sponsorship revenue, took UTXO into structured credit, and held Bitcoin Asia in Hong Kong. We also announced Intelligence 2027, our first event built around AI. i27 takes our events business behind The Bitcoin Conference into the intersection between AI, investment, enterprise adoption and policy.”

David Bailey, Chairman and Chief Executive Officer of Nakamoto

“Markets move in cycles, and we are building Nakamoto to perform through all of them, by extending our debt maturities and building operating businesses that earn revenue beyond our Bitcoin holdings. We are confident that these initiatives and our selective approach to deploying capital will help us drive sustainable earnings and long-term shareholder value.”

David Bailey, Chairman and Chief Executive Officer of Nakamoto
6:04 AM ET 10-Q
Financial Results Enovix Corp ENVX

Enovix Q3 2026 Results: Net Loss of $41.9M, Loss Narrows

Enovix Corp reported revenue of $11.0 million for the fiscal quarter ended October 4, 2026, up from $8.0 million in the prior year period. The company reduced its quarterly loss from operations to $39.3 million compared to $47.0 million in 2025, while maintaining a strong liquidity position with $405.5 million in cash and short-term investments.

Key figure
Net loss $41.9M
6:04 AM ET 10-Q
Financial Results HawkEye 360, Inc. HAWK

HawkEye 360 Q3 2026 Results: Net Loss of $163K

HawkEye 360, Inc. significantly strengthened its balance sheet in 2026, with cash and cash equivalents increasing to $494.9 million from $92.7 million at year-end 2025. The company transitioned from a stockholders' deficit to a total stockholders' equity of $805.3 million, primarily driven by the conversion of mezzanine equity and an increase in additional paid-in capital.

Key figure
Net loss $163K
6:04 AM ET 10-Q
Financial Results Gemini Space Station, Inc. GEMI

Gemini Space Station Q3 2026 Results: Net Loss of $58.6M, Loss Narrows

Gemini Space Station, Inc. reported a total asset decrease from $1.80 billion at year-end 2025 to $1.58 billion as of September 30, 2026, driven by declines in cash and crypto assets held. The company's accumulated deficit widened to $2.32 billion, reflecting ongoing net losses during the period.

Key figure
Net loss $58.6M
6:04 AM ET 10-Q
Financial Results Cartesian Growth Corp IV CGCF

Cartesian Growth Corp IV Q3 2026 Results: Net Income $2.34M

Cartesian Growth Corporation IV is a blank check company that completed its IPO in June 2026, raising $275 million. As of September 30, 2026, the company reported a net income of $2.3 million for the quarter, primarily driven by interest earned on investments held in the Trust Account, and is currently seeking a target for a business combination.

Key figure
Net income $2.34M
6:03 AM ET 10-Q
Financial Results GigCapital9 Corp. GIX

GigCapital9 Q3 2026 Results: Net Income $1.98M

GigCapital9 Corp. is a shell company that completed its initial public offering in January 2026, raising $253 million. For the nine months ended September 30, 2026, the company reported net income of $5.1 million, primarily driven by $6.1 million in interest and dividend income from marketable securities held in its Trust Account.

Key figure
Net income $1.98M
6:03 AM ET 10-Q
Financial Results Nova Minerals Corp NVA

Nova Minerals Q1 2026 Results: Net Loss of $12M, Loss Widens

Nova Minerals Corp reported a net loss of $12.0 million for the quarter ended September 30, 2026, compared to a $6.4 million loss in the prior year, driven primarily by increased exploration and evaluation expenses. The company is transitioning its focus toward developing a pilot-scale antimony processing facility in Alaska, supported by a $43.4 million award from the U.S. Department of War.

Key figure
Net loss $12M
6:03 AM ET 10-Q
Financial Results Silence Therapeutics plc SLN

Silence Therapeutics Q3 2026 Results: Net Loss of $12.4M, Loss Narrows

Silence Therapeutics reported a net loss of $39.7 million for the nine months ended September 30, 2026, a significant improvement from the $76.8 million loss in the prior year period. The company strengthened its balance sheet through a major share issuance in the third quarter, bringing cash and cash equivalents to $247.7 million, which management believes will fund operations until at least 2028.

Key figure
Net loss $12.4M
6:03 AM ET 10-Q
Financial Results York Space Systems Inc. YSS ▶ Call

York Space Systems Q3 2026 Results: Net Loss of $807M, Loss Widens

York Space Systems Inc. reported a significant increase in total current assets to $579.2 million as of September 30, 2026, driven by growth in cash and contract assets. The company is actively executing an M&A strategy, highlighting recent acquisitions of Orbion Space Technologies, Solestial Space Technology, and All.Space Holdings.

Key figure
Net loss $807M
6:03 AM ET 10-Q
Financial Results Bolt Biotherapeutics, Inc. BOLT

Bolt Biotherapeutics Q3 2026 Results: Net Loss of $4.42M, Loss Narrows

Bolt Biotherapeutics reported a net loss of $19.5 million for the nine months ended September 30, 2026, a significant reduction from the $26.7 million loss in the prior year period. The company recently acquired Prana Therapies, Inc. to pivot its focus toward the INSPIRE platform for multispecific antibodies while completing Phase 1/2 trials for BDC-4182.

Key figure
Net loss $4.42M
6:02 AM ET 8-K
Financial Results Immucell Corp ICCC

Immucell Financial Results

ImmuCell reported Q3 2026 financial results with revenue growing 46% to $8.0 million and net income of $953,000. The company highlighted broad-based growth across sales territories and announced the termination of its At-The-Market (ATM) offering program due to a strong cash position.

Term
Q3 2026

“ImmuCell had a strong quarter. The expanded commercial team is delivering solid revenue growth as we reach more customers with our value propositions. Increased commercial activity was supported by increased output from the manufacturing team. We are investing in capacity expansion and colostrum sourcing capabilities for future demand, and those efforts are projected to be completed on time and within budget.”

Olivier te Boekhorst, President and CEO

“Today we are reporting net income of $953,000 for the third quarter of 2026, a $1.1 million increase compared to the third quarter of 2025. Revenue grew 46.0% to $8.0 million in the third quarter of 2026 compared to the third quarter of 2025, a comparison aided in part by the absence of distributor restocking headwinds that had adversely affected the third quarter sales in 2025.”

Timothy C. Fiori, Chief Financial Officer
6:02 AM ET 10-Q
Financial Results Nektar Therapeutics NKTR

Nektar Therapeutics Q3 2026 Results: Net Loss of $55.7M, Loss Widens

Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on developing rezpegaldesleukin (NKTR-358) for autoimmune diseases. The company reported a transition to a non-accelerated filer status and continues to incur substantial net losses while relying on collaboration agreements and capital markets for funding.

Key figure
Net loss $55.7M
6:01 AM ET 10-K
Financial Results Tennessee Valley Authority TVE

Tennessee Valley Authority FY 2026 Results: Net Income $2.12B, Up 56.0% YoY

The Tennessee Valley Authority's 2026 10-K filing outlines its financial and operational structure, including new accounting standards and risk management activities. The document highlights significant environmental and regulatory matters, such as compliance with the 2015 CCR Rule and the Clean Air Act, alongside strategic initiatives like the Enterprise Transformation Program.

Key figure
Net income $2.12B · +56.0% YoY
6:01 AM ET 10-Q
Financial Results NeoVolta Inc. NEOV

NeoVolta Q1 2026 Results: Net Loss of $7.73M, Loss Widens

NeoVolta Inc. reported a significant revenue decline to $2.79 million for the quarter ended September 30, 2026, compared to $6.65 million in the prior year, resulting in a net loss of $7.73 million. The company significantly increased its cash position through a secured debt facility, ending the period with $25.97 million in cash and cash equivalents.

Key figure
Net loss $7.73M
6:01 AM ET 10-Q
Financial Results CV Sciences, Inc. CVSI

CV Sciences Q3 2026 Results: Net Loss of $93K, Loss Narrows

CV Sciences reported a net loss of $1.5 million for the nine months ended September 30, 2026, compared to a loss of $0.8 million in the prior year period, primarily driven by a decrease in product sales and non-cash losses on debt conversions. Despite the net loss, the company generated positive cash flow from operations of $0.18 million and recorded a $0.5 million gain from a legal settlement during the third quarter.

Key figure
Net loss $93K
6:01 AM ET 10-Q
Financial Results Karbon Capital Partners Corp. KBON

Karbon Capital Partners Q3 2026 Results: Turns Profitable, Net Income $3.06M

Karbon Capital Partners Corp. reported net income of $7.25 million for the nine months ended September 30, 2026, primarily driven by $9.42 million in interest earned on marketable securities held in trust. As a shell company, it has not yet generated operating revenue and is currently focused on identifying a target for a business combination.

Key figure
Net income $3.06M
6:01 AM ET 10-Q
Financial Results Marimed Inc. MRMD

Marimed Q3 2026 Results: Net Loss of $3.5M, Loss Widens

MariMed Inc. reported revenue of $44.2 million for the third quarter of 2026, a 9% increase year-over-year, though it recorded a net loss of $3.5 million due to high income tax provisions and interest expenses. The company's balance sheet shows $10.4 million in cash and a total of 405,996,010 common shares outstanding as of November 10, 2026.

Key figure
Net loss $3.5M
6:01 AM ET 10-Q
Financial Results Smartbird, Inc. BIRD

Smartbird Q3 2026 Results: Net Loss of $2.79M, Loss Narrows

Smartbird, Inc. (formerly Allbirds, Inc.) has completed the sale of its historical footwear business and is transitioning to a new AI Infrastructure Business. The company is currently an emerging growth company and reported 9,540,103 shares of Class A common stock outstanding as of November 3, 2026.

Key figure
Net loss $2.79M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.